The effects of saffron in patients with Non Small cell Lung cancer.

Evaluating the effects of the product containing saffron (Crocus sativus) on chronic fatigue syndrome and quality of life in patients with Non Small cell Lung cancer.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20241127063877N1

Enrollment

Registered

2025-03-01

Start date

2025-03-04

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Small cell Lung Cancer. Malignant neoplasm of unspecified part of unspecified bronchus or lung

Interventions

Intervention group: Received Duralife Saffron supplement containing 30 mg of standardized saffron extract (Crocus sativus), manufactured by Faran Shimi Pharmaceutical Company - Iran, which should be t

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients admitted to the hospital with a diagnosis of NSCLC

Exclusion criteria

Exclusion criteria: Having an allergy to saffron Patient in need of surgery Patient with tachycardia Pregnant and breastfeeding women Patients taking anticoagulants or having a coagulation disorder

Design outcomes

Primary

Measure	Time frame
Fatigue score in the BFI questionnaire, Quality of life score in the EQ_5F_3L questionnaire. Timepoint: Study start , 7,14, 21 & 28 days after starting saffron supplementation. Method of measurement: Patient file ,BFI fatigue questionnaire , EQ_5F_3L quality of life questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNiayesh Pirnia

Shahid Beheshti University of Medical Sciences

n.pirnia@sbmu.ac.ir+98 23 3332 8521

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026